Additionally, the 36-month beta value for QNRX is 1.32. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average trading volume of QNRX on May 14, 2025 was 208.63K shares.
QNRX) stock’s latest price update
Quoin Pharmaceuticals Ltd ADR (NASDAQ: QNRX)’s stock price has soared by 8.02 in relation to previous closing price of 6.36. Nevertheless, the company has seen a gain of 11.99% in its stock price over the last five trading days. globenewswire.com reported 2025-05-14 that ASHBURN, Va., May 14, 2025 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces positive initial clinical data from its ongoing Investigator Pediatric Peeling Skin Syndrome clinical study.
QNRX’s Market Performance
Quoin Pharmaceuticals Ltd ADR (QNRX) has experienced a 11.99% rise in stock performance for the past week, with a 30.12% rise in the past month, and a -38.47% drop in the past quarter. The volatility ratio for the week is 5.35%, and the volatility levels for the past 30 days are at 12.30% for QNRX. The simple moving average for the past 20 days is 8.57% for QNRX’s stock, with a -59.55% simple moving average for the past 200 days.
QNRX Trading at -13.71% from the 50-Day Moving Average
After a stumble in the market that brought QNRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.50% of loss for the given period.
Volatility was left at 12.30%, however, over the last 30 days, the volatility rate increased by 5.35%, as shares surge +15.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.14% lower at present.
During the last 5 trading sessions, QNRX rose by +10.84%, which changed the moving average for the period of 200-days by -68.09% in comparison to the 20-day moving average, which settled at $6.32. In addition, Quoin Pharmaceuticals Ltd ADR saw -69.83% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at QNRX starting from Carter Denise P., who purchase 555,556 shares at the price of $0.45 back on Dec 23 ’24. After this action, Carter Denise P. now owns 602,648 shares of Quoin Pharmaceuticals Ltd ADR, valued at $250,000 using the latest closing price.
Myers Michael, the Chief Executive Officer of Quoin Pharmaceuticals Ltd ADR, purchase 555,556 shares at $0.45 during a trade that took place back on Dec 23 ’24, which means that Myers Michael is holding 602,808 shares at $250,000 based on the most recent closing price.
Stock Fundamentals for QNRX
The total capital return value is set at -0.81. Equity return is now at value -138.80, with -71.84 for asset returns.
Currently, EBITDA for the company is -8.9 million with net debt to EBITDA at 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.57.
Conclusion
In conclusion, Quoin Pharmaceuticals Ltd ADR (QNRX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
